Switch theme
Sign up to access all valuation multiples
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognizes revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.
1999
83
LTM Revenue $9.7M
LTM EBITDA -$8.4M
$28.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Impedimed has a last 12-month revenue (LTM) of $9.7M and a last 12-month EBITDA of -$8.4M.
In the most recent fiscal year, Impedimed achieved revenue of $6.5M and an EBITDA of -$14.2M.
Impedimed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Impedimed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.7M | XXX | $6.5M | XXX | XXX | XXX |
| Gross Profit | -$9.1M | XXX | $5.6M | XXX | XXX | XXX |
| Gross Margin | -94% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | -$8.4M | XXX | -$14.2M | XXX | XXX | XXX |
| EBITDA Margin | -86% | XXX | -219% | XXX | XXX | XXX |
| EBIT | -$10.0M | XXX | -$15.6M | XXX | XXX | XXX |
| EBIT Margin | -103% | XXX | -242% | XXX | XXX | XXX |
| Net Profit | -$10.5M | XXX | -$12.7M | XXX | XXX | XXX |
| Net Margin | -108% | XXX | -197% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Impedimed's stock price is AUD 0 (or $0).
Impedimed has current market cap of AUD 60.8M (or $39.1M), and EV of AUD 44.2M (or $28.4M).
See Impedimed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28.4M | $39.1M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Impedimed has market cap of $39.1M and EV of $28.4M.
Impedimed's trades at 3.5x EV/Revenue multiple, and -2.6x EV/EBITDA.
Equity research analysts estimate Impedimed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Impedimed has a P/E ratio of -3.7x.
See valuation multiples for Impedimed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $39.1M | XXX | $39.1M | XXX | XXX | XXX |
| EV (current) | $28.4M | XXX | $28.4M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | -3.4x | XXX | -2.6x | XXX | XXX | XXX |
| EV/EBIT | -2.8x | XXX | -2.2x | XXX | XXX | XXX |
| EV/Gross Profit | -3.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.7x | XXX | -3.4x | XXX | XXX | XXX |
| EV/FCF | -3.1x | XXX | -2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImpedimed's last 12 month revenue growth is 67%
Impedimed's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Impedimed's rule of 40 is -132% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Impedimed's rule of X is 82% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Impedimed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 67% | XXX | 79% | XXX | XXX | XXX |
| EBITDA Margin | -86% | XXX | -135% | XXX | XXX | XXX |
| EBITDA Growth | -48% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -132% | XXX | -67% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 82% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 329% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Impedimed acquired XXX companies to date.
Last acquisition by Impedimed was XXXXXXXX, XXXXX XXXXX XXXXXX . Impedimed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Impedimed founded? | Impedimed was founded in 1999. |
| Where is Impedimed headquartered? | Impedimed is headquartered in Australia. |
| How many employees does Impedimed have? | As of today, Impedimed has 83 employees. |
| Is Impedimed publicy listed? | Yes, Impedimed is a public company listed on ASX. |
| What is the stock symbol of Impedimed? | Impedimed trades under IPD ticker. |
| When did Impedimed go public? | Impedimed went public in 2007. |
| Who are competitors of Impedimed? | Similar companies to Impedimed include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Impedimed? | Impedimed's current market cap is $39.1M |
| What is the current revenue of Impedimed? | Impedimed's last 12 months revenue is $9.7M. |
| What is the current revenue growth of Impedimed? | Impedimed revenue growth (NTM/LTM) is 67%. |
| What is the current EV/Revenue multiple of Impedimed? | Current revenue multiple of Impedimed is 2.9x. |
| Is Impedimed profitable? | Yes, Impedimed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Impedimed? | Impedimed's last 12 months EBITDA is -$8.4M. |
| What is Impedimed's EBITDA margin? | Impedimed's last 12 months EBITDA margin is -86%. |
| What is the current EV/EBITDA multiple of Impedimed? | Current EBITDA multiple of Impedimed is -3.4x. |
| What is the current FCF of Impedimed? | Impedimed's last 12 months FCF is -$9.0M. |
| What is Impedimed's FCF margin? | Impedimed's last 12 months FCF margin is -93%. |
| What is the current EV/FCF multiple of Impedimed? | Current FCF multiple of Impedimed is -3.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
